AS01-ADJUVANTED recombinant zoster vaccine
1 paper studies it3 findings
- 1 lab in 2 countries
- Funders: Dutch Research Council and 4 more
- 2 of 2 findings with company ties
- Human trial1
Outcomes
3Herpes zoster
downin humans1−82% protection
1 study
Herpes zoster
downin humans1−82% protection
AS01-ADJUVANTED recombinant zoster vaccine protects against herpes zoster in humans (82% protection).
“offering 82% protection against herpes zoster at 11 years after vaccination in individuals over 50.”
Review
JCI insightJun 2, 2026
Antigen-specific polyfunctional CD4+ T cells
upin humans1
1 study
Antigen-specific polyfunctional CD4+ T cells
upin humans1
AS01-ADJUVANTED recombinant zoster vaccine increases antigen-specific polyfunctional CD4+ T cells in humans.
“RZV elicited robust antibody production, antigen-specific polyfunctional CD4+ T cell responses, and IFN-γ from PBMCs in both age groups”
Human trialyoung and older adults
JCI insightJun 2, 2026
Inflammation
downin humans1
1 study
Inflammation
downin humans1
AS01-ADJUVANTED recombinant zoster vaccine decreases inflammation in humans.
“RZV reduced systemic inflammation in older adults, particularly after the second injection.”
Human trialolder adultsn = 63
JCI insightJun 2, 2026
Latest
1 paper in 12 monthsJCI Insight
Age-related differences in immune responses to inactivated influenza and adjuvanted recombinant herpes zoster vaccines
Randomized trial in peopleHerpes zoster